Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma
NCT00521638
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Subjects with CD20-positive, B cell NHL who, after at least 2 prior therapies of probable clinical benefit, have relapsed or refractory disease. The following histologies may be included*: lymphoplasmacytic lymphoma (formerly known as lymphoplasmacytoid lymphoma), splenic marginal zone B cell lymphoma, extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large-cell B cell lymphoma, and mediastinal large B cell lymphoma. Small lymphocytic lymphoma will be included if it is a primary diagnosis and if the lymphoma cells are < 5.0 x 109/L (5000/mm3) in the peripheral blood. *Subjects enrolled in the preliminary efficacy cohorts must have relapsed, refractory, or persistent follicular lymphoma (persistent disease defined as computed tomography (CT) positive for 3 months after last treatment), and must not have received anti-CD20 targeted therapy within 3 months of receiving the first dose of test article. Subjects may be considered eligible after a single therapy of probable clinical benefit, if no further standard effective treatment is available in the opinion of the investigator. Prior CD20 immunophenotyping of tumors to document B cell NHL is acceptable. If such prior documentation is not available, then the immunophenotype of the current disease must be documented by fine-needle aspirate or biopsy, or by circulating CD20-positive NHL cells from peripheral blood before administration of test article.
- At least 1 measurable lesion that is 1.5 cm in at least 1 dimension by CT or magnetic resonance imaging (MRI), in an area of no prior radiation therapy, or documented progression in an area that was previously irradiated.
- Recovery to baseline or grade 1 [according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0] from all acute adverse effects of prior therapies (excluding alopecia).
Main
- Candidate for potentially curative therapy that is available to the subject, in the
clinical opinion of the investigator.
- Diagnosis of chronic lymphocytic leukemia, Burkitt's lymphoma, primary effusion
lymphoma, and/or precursor B cell lymphoblastic lymphoma.
- Prior treatments: radioimmunotherapy; allogeneic hematopoietic stem cell transplant
(within 6 months of first dose of study drug); chemotherapy, cancer immunosuppressive
therapy, growth factors (except erythropoietin), or investigational agents (within 4
weeks of first dose of study drug); major surgery not related to debulking surgical
procedures (within 3 weeks of first dose of study drug).
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Duarte, California
- San Diego, California
- Chicago, Illinois
- Boston, Massachusetts
- St. Louis, Missouri
- Buffalo, New York
- Cleveland, Ohio
- Aichi,
- Kanagawa,
- Tokyo,
- Tokyo,
- Maywood, Illinois
- Boston, Massachusetts
- Ann Arbor, Michigan
- Saint Louis, Missouri
- Saint Louis, Missouri
- Saint Peters, Missouri
- Hackensack, New Jersey
- Hackensack, New Jersey
- Hackensack, New Jersey
- Hackensack, New Jersey
- Hackensack, New Jersey
- New York, New York
- Hershey, Pennsylvania
- Dallas, Texas
- Dallas, Texas
- Dallas, Texas
- Houston, Texas
- Houston, Texas
- San Antonio, Texas
- Madison, Wisconsin
- Madison, Wisconsin
- Lille,
- Marseille,
- Montpellier Cedex 5,
- Paris,
- Pessac,
- Pierre-Benite cedex 114,
- Pierre-benite Cedex,
- Strasbourg,
- Berlin,
- Seoul, Gangnam-gu
- Seoul, Seoul/korea
- Seoul,
- Singapore,
- Manchester,
- Manchester,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma | |||
Official Title ICMJE | A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects With Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma | |||
Brief Summary | This is a study to evaluate the safety and efficacy of TRU-015 in treatment of B-cell Non-Hodgkin's Lymphoma (NHL). TRU-015 is also currently being evaluated in multiple clinical studies for the treatment of autoimmune disorders. Over 300 patients have received TRU-015 in these studies, and the data observed to date support its safety in patients with autoimmune disorders. Safety of an escalating dose of 4 weekly infusions of TRU-015 will be evaluated in subjects with relapsed NHL (see inclusion criteria for subtypes). Once a maximum tolerated dose (MTD) is confirmed or maximum dose to be studied is determined to be safe and well tolerated, an expanded cohort of subjects with relapsed follicular NHL will be evaluated for efficacy. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 1 Phase 2 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Lymphoma, B-Cell | |||
Intervention ICMJE | Biological: TRU-015
Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks | |||
Study Arms ICMJE | Experimental: 1
Intervention: Biological: TRU-015 | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Estimated Enrollment ICMJE | 120 | |||
Original Estimated Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | April 2008 | |||
Actual Primary Completion Date | April 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Main Inclusion Criteria:
Main Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00521638 | |||
Other Study ID Numbers ICMJE | 3206K2-104 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth | |||
Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Collaborators ICMJE | Emergent Product Development Seattle LLC | |||
Investigators ICMJE |
| |||
PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Verification Date | January 2013 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |